Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gap junction gamma-1 protein (GJC1), also known as connexin-45 (Cx45) or gap junction alpha-7 protein (GJA7), is a member of the connexin gene family that forms gap junction channels in cell membranes, enabling direct cell-to-cell communication by allowing diffusion of ions and small molecules (up to 1 kDa) between adjacent cells[1][3][4]. This protein is especially important in tissues requiring rapid electrical or metabolic coupling, such as the heart and nervous system, and plays a critical role in regulating physiological coordination at the multicellular level. Defects in GJC1 have been associated with disorders such as heart disease and oculodentodigital dysplasia[1][3][4].
Modulation of gap junction channel activity (for any therapeutic agents known to affect connexins generally; specific GJC1 modulators not indicated)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gap junction gamma-1 protein (GJC1).